Press releases
US-specific press releases are available here. Please visit our global website for access to global press releases dating back to 2009.
-
ViiV Healthcare submits New Drug Application to US FDA for the first monthly, injectable, two-drug regimen of cabotegravir and rilpivirine for treatment of HIV
If approved, cabotegravir and rilpivirine would be the first-ever long-acting, injectable treatment regimen for adults living with HIV
Read more -
GSK receives US approval of Benlysta for intravenous use in children with lupus aged five years and above
FDA approval marks the first medicine in the US approved for children with systemic lupus erythematosus (SLE)
Read more -
ViiV Healthcare announces CHMP Positive Opinion for Dovato® (dolutegravir/lamivudine) as a once-daily, single-pill, two-drug regimen for the treatment of HIV infection
ViiV Healthcare announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending ...
Read more -
GSK invests $100 million to expand long-term vaccine manufacturing capabilities in Hamilton, MT
GSK today announced $100 million of new investment in its manufacturing site in Hamilton, Montana to expand the production capacity of key components of the adjuvant system used...
Read more -
Eighty Philadelphia teachers to attend “Empowering STEM” on Monday, April 8th
Empowering STEM is full-day conference supporting teachers in tackling Philadelphia’s STEM career challenge.
Read more -
US FDA approves ViiV Healthcare’s Dovato (dolutegravir/lamivudine), the first, once-daily, single-tablet, two-drug regimen for treatment-naïve HIV-1 adults
Approval based on GEMINI pivotal trials in which Dovato achieved non-inferior efficacy compared to a dolutegravir-based, traditional, three-drug regimen through 48 weeks, with n...
Read more -
ViiV Healthcare announces Juluca (dolutegravir/rilpivirine) maintains HIV viral suppression at 148-weeks
SWORD studies demonstrate long-term durable efficacy and tolerability of Juluca, the first complete 2-drug regimen, for the treatment of virologically suppressed adults with HIV.
Read more -
GSK announces further positive data from DREAMM-1 study of anti-BCMA antibody-drug conjugate in patients with relapsed/refractory multiple myeloma
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced further positive data from the DREAMM-1 study of patients with relapsed/refractory multiple myeloma who received GSK2857916, ...
Read more -
Middle school teachers get hands-on experience in STEM careers
Second annual emPowering STEM Classroom to Career Conference to take place in RTP March 25th
Read more -
Data from GARNET study indicates robust activity of dostarlimab in patients with advanced or recurrent endometrial cancer
TESARO, an oncology-focused business acquired by GlaxoSmithKline plc (LSE/NYSE: GSK), announced today the presentation of data from the Phase 1/2 GARNET study evaluating dostarl...
Read more -
GSK sponsors GSK Science in the Summer™ with Morehead Planetarium
Morehead Planetarium & Science Center is partnering with GSK for the 11th year to present GSK Science in the Summer™
Read more -
ViiV Healthcare presents positive, 48-week data from two pivotal phase III studies showing long-acting, injectable two-drug regimen of cabotegravir and rilpivirine has similar efficacy to daily, three-drug oral treatment in adults living with HIV-1 infection
Comprehensive data from ATLAS and FLAIR studies presented today at the 2019 Conference on Retroviruses and Opportunistic Infections show investigational long-acting injectable t...
Read more -
GSK receives a positive CHMP opinion for intravenous zanamivir for the treatment of complicated influenza
GSK today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for intravenous zanamivir...
Read more -
GSK Science in the Summer™ unveils 2019 curriculum: The Science of Me
Free STEM program in partnership with The Franklin Institute to reach 26,000 students nationwide this year.
Read more -
GSK delivers sales, earnings and cash flow growth in 2018
Total EPS 73.7p, +>100% AER, +>100% CER; Adjusted EPS 119.4p +7% AER, +12% CER
Read more -
GSK and Merck KGaA, Darmstadt, Germany announce global alliance to jointly develop and commercialize M7824, a novel immunotherapy with potential in multiple difficult-to-treat cancers
GSK and Merck KGaA, Darmstadt, Germany today announced that they have entered into a global strategic alliance
Read more -
GSK completes acquisition of TESARO, an oncology focused biopharmaceutical company
GSK announced that it has successfully completed the acquisition of TESARO, Inc. an oncology-focused company
Read more -
GSK announces succession plan to appoint new Chairman
GSK announces that Sir Philip Hampton has informed the Board of his intention to step down as non-executive Chairman
Read more -
Two positive phase III studies of tafenoquine for the radical cure of Plasmodium vivax malaria published in The New England Journal of Medicine
GSK today announced the publication of positive results from two phase III studies of single-dose tafenoquine
Read more -
GlaxoSmithKline plc and Pfizer Inc to form new world-leading Consumer Healthcare Joint Venture
GSK has reached agreement with Pfizer Inc to combine their consumer health businesses into a new world-leading Joint Venture.
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We make a wide range of prescription medicines, vaccines and consumer healthcare products.
-
Research and development
Driving scientific innovation to deliver the next generation of transformational medicines and vaccines for patients.
